Pedal the Cause announced the cancer research projects that will be funded from last year’s cycling fundraiser. The projects are geared toward the steps needed to take discoveries “from bench to beside.”
Karen Hooper (right), executive vice president of the National MS Society’s Pacific South Coast Chapter, presenting Dr. Barbara Ranscht (left) with the chapter’s Researcher of the Year Award at the March 24 event.
San Diego biotech reports good news on its treatment for non-alcoholic liver disease.
Aridis Pharmaceuticals Commences Phase 1 Clinical Study of Aerucin™ Monoclonal Antibody for Acute Pneumonia
Study Expected to Complete in 3Q 2015
SAN JOSE, Calif., March 26, 2015 /PRNewswire/ — Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel therapies for infectious diseases, announced today the initiation of a Phase 1 clinical study of Aerucin™, the Company’s fully human IgG1 monoclonal antibody (mAb) against Pseudomonas aeruginosa bacteria, which is being developed as an adjunctive treatment for acute pneumonia. Aerucin has also filed for Orphan Disease Designation with the U.S. Food and Drug Administration in the United States and in Europe.
The clinical trial, expected to complete in the third quarter of 2015, is a Phase 1 single ascending dose study in healthy volunteers. Advancing to this stage of development represents the culmination of longstanding collaborations with Harvard University and the National Institutes of Health.
Founder and Chief Executive Officer, Vu Truong, Ph.D., stated, “We are pleased to initiate an accelerated clinical development plan to generate proof-of-concept data that further characterize Aerucin’s bactericidal potency. We believe that directing the human immune response to fight life-threatening infections such as those associated with Gram-negative P. aeruginosa bacteria represents the future of new anti-infectives, and will be critical to solving the persistent problem of antibiotic resistance.”
Aerucin directly binds the alginate polysaccharide on the cell surface of P. aeruginosa. It was discovered using Aridis’ proprietary MabIgX® technology by screening human B-cells for antibodies that demonstrated improved immune recognition and phagocytic destruction of more than 90% of all Pseudomonas aeruginosa. Earlier preclinical studies of Aerucin support both therapeutic and prophylactic use of the monoclonal antibody.
About Aridis Pharmaceuticals, Inc.
Aridis is a privately held biopharmaceutical company applying proprietary monoclonal antibody discovery technology MabIgX® and pharmaceutical formulation technologies to produce novel infectious disease focused therapies. Aridis’ product pipeline includes AR-301 anti-Staphylococcus aureus human monoclonal antibody to treat acute pneumonia; AR-101 anti-Pseudomonas aeruginosa LPS human monoclonal antibody; Panaecin™, a small molecule anti-infective gallium compound with broad spectrum activities against bacteria, viruses, and fungi; Aerucin™, a broadly reactive monoclonal antibody against Pseudomonas aeruginosa initially being developed to treat acute pneumonia; AR- 401 anti-Acinetobacter baumannii human monoclonal antibody; and AR-201 anti-RSV human monoclonal antibody.
Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements relating to the therapeutic applications of AR-301, AR-101, Panaecin™, Aerucin™, AR-401, AR-201, Aridis’ proprietary formulation and delivery technologies, about Aridis’ strategy, pre-clinical and clinical programs, and ability to identify and develop drugs, as well as other statements that are not historical facts. Actual events or results may differ materially from Aridis’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the timing, success and cost of Aridis’ research and clinical studies and its ability to obtain additional financing. These forward-looking statements represent Aridis’ judgment as of the date of this release. Aridis disclaims any intent or obligation to update these forward-looking statements.
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (investors)
Amy Wheeler (media)
SOURCE Aridis Pharmaceuticals, Inc.
CA-Carlsbad, Experienced Assembler – biomedical / medical device, Carlsbad, CA Our client, a leading clinical diagnostics company, is seeking an Assembler with medical device assembly experience to join their team in Carlsbad, CA. This is a long-term, …
SAN DIEGO, March 26, 2015 /PRNewswire/ – BioNano Genomics, Inc., the leader in genome mapping, announced today the appointment of Terry Salyer as chief commercial officer. Salyer has more than 20 years of experience building highly effective, worldwide sales teams in life sciences. At BioNano, Salyer will oversee the commercialization of BioNano’s Irys® System, a genome-mapping platform to assemble a comprehensive view of complex genomes to help discover and investigate structural variations. To date, 32 institutions located in the United States, Europe and Asia Pacific, already own an Irys System, and BioNano recently expanded its existing Asia-Pacific distribution to Japan.
“The ability to robustly discover structural variations and to complete genome assemblies has made BioNano’s Irys System an essential tool to advance genomic research and applications,” said Erik Holmlin, Ph.D., president and CEO of BioNano Genomics. “We look forward to working with Terry, who will lead and build BioNano’s worldwide sales teams for significant growth and adoption of the Irys System.”
Genome maps built using the Irys System can help reveal significant order and orientation of relevant genetic components that have biological and clinical relevance. These include genes, promoters, regulatory elements, the length and location of long areas of repeats, as well as viral integration sites. As a whole, these structural variations have been termed the “inaccessible genome,” because they are often missed by the existing repertoire of genomics tools.
“I was impressed with how the Irys System allows scientists to reach the ‘inaccessible genome’ with a single, cost-effective technology platform,” said Salyer. “The BioNano team has created the only commercial genome mapping system, and I look forward to helping genomics researchers access the Irys System to obtain a comprehensive view of complex genomes.”
Prior to joining BioNano Genomics, Salyer was the vice president of worldwide sales at ProteinSimple where she doubled the revenue growth. Previous to ProteinSimple, she was vice president of worldwide sales at ForteBio, where she held a critical role in successfully selling the business to Pall Corporation. Salyer’s previous positions include vice president of worldwide sales and service at Eksigent Technologies and director of sales at Molecular Devices. At Molecular Devices, Terry was director of the Western region and had responsibility for sales of all life sciences products. Terry holds a B.S. in biotechnology from Minnesota State at Mankato.
Irys makes it possible to routinely and accurately detect genomic structural variation and to finish genome assemblies. The fully automated Irys benchtop instrument uses the IrysChip to uncoil and confine long DNA molecules in proprietary Nanochannel Arrays™ where they are uniformly linearized in a highly parallel display for high-resolution, single-molecule imaging. Irys does not employ DNA fragmentation or amplification, which are typical with next-generation sequencing. The result is sequence information over extremely long “reads” ranging from hundreds of kilobases to a megabase, where the sample’s valuable structural information is preserved. Irys makes it possible for researchers to directly observe structural variants including replications, deletions, translocations and inversions.
About BioNano Genomics
Headquartered in San Diego, BioNano Genomics is delivering an altogether better way of gaining a fully informed understanding of genomes. The Company’s platform provides researchers and clinicians the most comprehensive, organized and actionable picture of a genome with unprecedented insights into how the individual components of genomes are ordered, arranged, and interact with each other. BioNano Genomics works with institutions in life science, translational research, molecular diagnostics and personalized medicine. The Company is supported by private investors and grant funding from genomics programs at federal agencies, including the NIH and NIST-ATP.
Notes: BioNano Genomics is a trademark of BioNano Genomics, Inc. Any other names of actual companies, organizations, entities, products or services may be the trademarks of their respective owners.
SOURCE BioNano Genomics
Our customers include a broad range of academic, government, pharmaceutical, biotechnology, and other leading institutions around the globe….
From Illumina, Inc. – 26 Mar 2015 09:40:06 GMT
– View all San Diego jobs
Provides weekly sales activity reports to management. Uses SFDC to manage internal communication and document territory and client information as required for…
From Covance – 26 Mar 2015 08:09:55 GMT
– View all San Diego jobs
SANTA CLARA, Calif., March 26, 2015 /PRNewswire/ — Finesse Solutions announced Cellworld 2015, a new event that is specifically designed for innovators, visionaries and senior executives in bio-processing.
The two day conference, by invitation only, will be held at the Hyatt Regency in Downtown San Francisco on September 21-22, 2015. It will be a forum for life science leaders to discuss the future of single-use biopharmaceutical manufacturing and to hear about both disruptive technologies and best practices from all facets of our industry.
The event sessions will cover both upstream and downstream single-use bio-processing with a focus on innovation through the use of novel measurement and automation systems. It will introduce new tools for managing process complexity and the resulting intelligent meta-data. Topics will range from new single-use sensors to implementing commercial-off-the-shelf, highly configurable manufacturing execution systems (MES) for single-use facilities.
“Our goal is to provide the senior leadership in bio-processing with a glimpse of the future in order to fully exploit single-use technologies and to remain globally competitive,” stated Barbara Paldus, CEO of Finesse Solutions. “We are very excited to create the first international forum to explore innovation and technology, so that as a community, we can accelerate the adoption of new bio-processing platforms and fully exploit highly intelligent tools that are rapidly becoming available through advances in electronics, software, and communications.”
About Finesse Solutions, Inc.
Finesse Solutions provides flexible hardware and software automation which allows for unmatched customizable bioprocessing. We are a research based, Silicon Valley company who believes in empowering our clients with innovative single-use sensors, bioreactors, controllers and software. Our SmartParts are the foundation of a Finesse solution using technologies from inside and outside of the biopharmaceutical industry. In addition to our own products, we are the only supplier with integration expertise offering clients the independence to select any preferred supplier of key unit operations from upstream to downstream. Whether it’s a stand-alone, single-use bioreactor for research and development or a fully integrated Smartfactory for cGMP-compliant manufacturing, we have a bioprocess solution for our customers.
For more information, please visit us at
SOURCE Finesse Solutions, Inc.
Details: Job Duties: Manage all aspects of the recruitment process including requisition preparation and approval, job postings, advertisements, resume screening, interviews, reference checks, presenting offers etc. Maintain resume tracking logs and op…